This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

This study has been completed.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01499277
First received: December 16, 2011
Last updated: November 18, 2015
Last verified: November 2015
Results First Received: June 23, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil
Drug: Vancomycin
Drug: Aztreonam

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Overall, 802 patients were enrolled from 111 centres in 6 regions in this study. The first patient was enrolled on 17 May 2012 and the last patient last visit was on 26 June 2014. Of 802 enrolled participants, 30 did not meet the eligibility criteria and 11 were randomized but not treated.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ceftaroline Ceftaroline fosamil at 600 mg every 8 hours (q8h)
Vancomycin/Aztreonam Vancomycin Plus Aztreonam

Participant Flow:   Overall Study
    Ceftaroline   Vancomycin/Aztreonam
STARTED   506   255 
COMPLETED   459   223 
NOT COMPLETED   47   32 
Adverse Event                3                6 
Death                3                2 
Lost to Follow-up                15                8 
Protocol Violation                2                3 
Withdrawal by Subject                16                6 
Lack of therapeutic response and other                8                7 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
761 randomized patients who received any amount of study therapy. there are 11 patients who are randomized , but didn't receive any study therapy.

Reporting Groups
  Description
Ceftaroline Ceftaroline fosamil at 600 mg every 8 hours (q8h)
Vancomycin/Aztreonam Vancomycin Plus Aztreonam
Total Total of all reporting groups

Baseline Measures
   Ceftaroline   Vancomycin/Aztreonam   Total 
Overall Participants Analyzed 
[Units: Participants]
 506   255   761 
Age 
[Units: Years]
Mean (Standard Deviation)
 52.6  (16.51)   53.6  (16.25)   52.9  (16.42) 
Gender 
[Units: Participants]
     
Female   196   107   303 
Male   310   148   458 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set   [ Time Frame: 7 to 20 days after the last dose of study drug ]

2.  Primary:   Clinical Response at TOC in Clinically Evaluable (CE) Analysis Set   [ Time Frame: 7 to 20 days after the last dose of study drug ]

3.  Secondary:   Per Patient Microbiological Response at TOC in Microbiologically Modified-intent-to-treat (mMITT) Analysis Set   [ Time Frame: 7 to 20 days after the last dose of study drug ]

4.  Secondary:   Per-patient Micro Response at TOC in Microbiologically Evaluable (ME) Analysis Set   [ Time Frame: 7 to 20 days after the last dose of study drug ]

5.  Secondary:   Clinical Response at End of Treatment (EOT) in MITT Analysis Set   [ Time Frame: On day of last dose of study drug (or + 1 day) ]

6.  Secondary:   Clinical Response at EOT in CE Analysis Set   [ Time Frame: On day of last dose of study drug (or +1 day) ]

7.  Secondary:   Clinical Relapse at Late Follow-up (LFU) in CE Patients Who Were Cured at TOC   [ Time Frame: 21 to 42 days after the last dose of study drug ]

8.  Secondary:   Early Response at 48 to 72 Hours of Treatment in MITT Analysis Set   [ Time Frame: 48 to 72 hours after first dose of study drug ]

9.  Secondary:   Per-pathogen Microbiological Response at TOC by Baseline Pathogen From Site of Skin Infection in ME   [ Time Frame: 7 to 20 days after the last dose of study drug ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Yunxia Lu
Organization: AstraZeneca-PPD
phone: 910-558-4197
e-mail: Yunxia.Lu@ppdi.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01499277     History of Changes
Other Study ID Numbers: D3720C00001
2011-004013-16
Study First Received: December 16, 2011
Results First Received: June 23, 2015
Last Updated: November 18, 2015